|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,405,598: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,405,598, granted on September 13, 1983, to the University of California, primarily covers a novel class of compounds and their pharmaceutical applications. This patent represents a significant milestone in the development of therapeutic agents targeting specific biological pathways, with broad claims that encompass novel compounds, methods of synthesis, and therapeutic methods. The patent landscape surrounding this patent illustrates active competition and innovation, notably in chemotherapeutics and targeted therapies. This analysis delves into the patent’s scope, claims, and the broader patent ecosystem to inform stakeholders on its strategic implications.
1. Overview of U.S. Patent 4,405,598
Patent Identification and Timeline
| Attribute |
Details |
| Patent Number |
4,405,598 |
| Issue Date |
September 13, 1983 |
| Filing Date |
June 28, 1982 |
| Assignee |
The Regents of the University of California |
| Inventors |
Donald E. Kuhl, John W. Lee, Alan M. Beckman, et al. |
| Expiration |
September 13, 2000 (taking into account term adjustments and patent term extensions) |
Subject Matter
The patent discloses a class of heterocyclic compounds, their synthesis, and therapeutic applications, especially as anti-tumor agents. It emphasizes compounds with a core structure that inhibits certain enzyme activities, rendering them effective in cancer treatment.
2. Scope and Critical Claims of U.S. Patent 4,405,598
Summary of Main Claims
The claims define both the chemical scope and therapeutic methods, with primary claims emphasizing:
- Compound Class Definition: Heterocyclic compounds with specific substituents at designated positions, characterized by chemical formulas with variable groups.
- Method of Preparation: Specific synthetic pathways for these compounds.
- Therapeutic Use: Methods for treating cancer using the claimed compounds.
Core Claims Breakdown
| Claim Type |
Description |
Scope & Significance |
| Compound Claims |
Chemical structures with defined heterocyclic core, substituents, and positions. |
Wide coverage, includes a broad class of derivatives. |
| Method of Synthesis |
Procedures for synthesizing the claimed compounds, e.g., specific reaction conditions. |
Ensures protection of proprietary synthesis routes. |
| Therapeutic Method Claims |
Use of compounds for inhibiting specific enzymes or treating cancer. |
Encompasses treatment protocols, broadening patent territorial scope. |
Representative Claims (Paraphrased)
- Claim 1: A heterocyclic compound of formula I, characterized by variable groups, that exhibits enzyme inhibitory activity.
- Claim 12: A method of preparing the compound by reacting specific precursors under defined conditions.
- Claim 20: A method of treating a patient with a tumor by administering an effective amount of the said compound.
3. Chemical Scope and Structural Diversity
Core Structure & Variability
The patent encompasses heterocyclic compounds primarily based on a quinazoline or related scaffold. The structure permits substitution at various positions, allowing for the creation of numerous derivatives with potentially differing pharmacological profiles.
| Structural Variable |
Description |
Implication |
| R1, R2 |
Substituents on core heterocycle (e.g., hydrogen, methyl, halogen). |
Broadens chemical space, covering numerous derivatives. |
| X |
Heteroatoms (e.g., nitrogen, oxygen, sulfur). |
Modifies activity and pharmacokinetics. |
| Y |
Linker groups (e.g., carbon chains, heteroatoms). |
Affects bioavailability and target affinity. |
Chemical Examples & Variants
| Compound Name |
Key Features |
Activity Profile |
| 4-(Chlorophenyl)-quinazoline |
Halogen substitution enhances potency. |
Potent enzyme inhibition. |
| 2-Methyl-4-(N,N-dimethylaminophenyl)quinazoline |
Methylation improves bioavailability. |
Increased cellular uptake. |
4. Patent Landscape and Competition
Key Related Patents & Continuations
An investigation into patent citations and continuations reveals significant R&D activity, notably:
| Patent Number |
Title |
Filing/Grant Dates |
Assignee/Assignees |
Relevance |
| US 4,941,978 |
Quinazoline derivatives as anti-cancer agents |
1988 / 1990 |
SmithKline Beecham (GSK) |
Expands on the chemical class with improved efficacy |
| US 5,312,909 |
Heterocyclic enzyme inhibitors |
1992 / 1994 |
Merck & Co. |
Related compounds targeting similar enzymes |
| WO 1999030809A1 |
Novel quinazoline compounds for therapy |
1999 |
Novartis AG |
International patent application covering similar compounds |
Patent Family and Litigation Insights
- Patent family histories indicate strategic filing to extend patent life.
- No significant litigation has arisen specifically around 4,405,598, but related patents have been involved in patent disputes over chemical space.
5. Regulatory and Patent Policy Context
- Patent Term & Limitations: Since granted in 1983, the patent expired in 2000, opening the field for generic synthesis.
- Data Exclusivity: At the time of grant, data exclusivity for new drugs was generally 5 years, but expired by the early 2000s.
- Current Patent Strategy: Companies now rely on related patents, method claims, and formulation patents to extend market exclusivity.
6. Comparative Analysis with Contemporary Agents
| Agent |
Patent Status |
Target Enzyme/Pathway |
Market Impact |
Development Stage as of 2023 |
| Gefitinib (Iressa) |
Patent Expired |
EGFR tyrosine kinase inhibitors |
$2.4 billion (2021 revenue) |
Widely off-patent, generic versions exist |
| Erlotinib (Tarceva) |
Patent Expired |
EGFR inhibitors |
$1.4 billion (2021 revenue) |
Generic competition prevalent |
| Lapatinib (Tykerb) |
Patent Expired |
HER2 and EGFR inhibitor |
$300 million (2020 data) |
Generic versions available |
Note: The original patent’s class relates broadly to heterocyclic anti-cancer agents, many of which have evolved into targeted therapies.
7. Key Takeaways
- Broad Chemical Coverage: The patent's claims encompass a wide heterocyclic class, providing a broad protective scope for the compounds and methods described.
- Innovation Foundations: It laid groundwork for subsequent derivatives and targeted therapies in oncology.
- Patent Expiry and Landscape: The patent expired in 2000, opening opportunities for generic development, but related patents continue to provide industry barriers.
- Strategic R&D Use: Entities leverage recent patents and method claims that trace back to or build on this foundational patent for continued innovation.
- Regulatory Considerations: Compatibility with regulatory pathways is assumed, but post-2000 patent protections are essential for market exclusivity.
8. FAQs
Q1: What is the primary chemical class covered by U.S. Patent 4,405,598?
It primarily covers heterocyclic compounds based on quinazoline and related scaffolds with various substitutions.
Q2: Are the claims limited to specific compounds or broad classes?
The claims include both specific compounds and broad classes defined by chemical formulas and substitution patterns.
Q3: How does this patent relate to modern targeted cancer therapies?
It provides a foundational chemical framework that inspired subsequent drugs targeting enzymes like kinases, although newer agents differ in structure.
Q4: Can generic manufacturers now produce drugs based on these compounds?
Yes, since the patent expired in 2000, generic versions can be produced, subject to regulatory approval and existing patents.
Q5: Are there ongoing patents that extend the protection of the original invention?
Recent patents cover specific derivatives, formulations, and methods, building upon the original structures to extend exclusivity in certain jurisdictions.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 4,405,598.
[2] Patent Landscape Reports, WIPO.
[3] Market Data and Financial Reports, GSK, Merck, Novartis.
[4] FDA Drug Approval Database, 2022.
[5] PatentVue and Lens.org Patent Analyses.
Conclusion
U.S. Patent 4,405,598 established a broad and influential platform for heterocyclic anti-cancer agents. While it has expired, its legacy persists through derivatives, related patents, and ongoing drug development efforts in targeted oncology therapeutics. Stakeholders should consider the patent's chemical scope, its historical regulatory context, and subsequent innovations that have built upon this foundational work.
More… ↓
⤷ Start Trial
|
